Annual EBITDA
$39.89 M
+$240.74 M+119.86%
December 31, 2023
Summary
- As of February 22, 2025, AMLX annual EBITDA is $39.89 million, with the most recent change of +$240.74 million (+119.86%) on December 31, 2023.
- During the last 3 years, AMLX annual EBITDA has risen by +$79.88 million (+199.75%).
- AMLX annual EBITDA is now at all-time high.
Performance
AMLX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$39.24 M
+$13.99 M+26.28%
September 30, 2024
Summary
- As of February 22, 2025, AMLX quarterly EBITDA is -$39.24 million, with the most recent change of +$13.99 million (+26.28%) on September 30, 2024.
- Over the past year, AMLX quarterly EBITDA has dropped by -$58.26 million (-306.27%).
- AMLX quarterly EBITDA is now -291.57% below its all-time high of $20.48 million, reached on June 30, 2023.
Performance
AMLX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$212.04 M
-$58.26 M-37.88%
September 30, 2024
Summary
- As of February 22, 2025, AMLX TTM EBITDA is -$212.04 million, with the most recent change of -$58.26 million (-37.88%) on September 30, 2024.
- Over the past year, AMLX TTM EBITDA has dropped by -$205.29 million (-3038.60%).
- AMLX TTM EBITDA is now -631.57% below its all-time high of $39.89 million, reached on December 31, 2023.
Performance
AMLX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AMLX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +119.9% | -306.3% | -3038.6% |
| 3 y3 years | +199.8% | -306.3% | -3038.6% |
| 5 y5 years | +420.7% | -306.3% | -3038.6% |
AMLX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +119.9% | -291.6% | +67.8% | -631.6% | at low |
| 5 y | 5-year | at high | +119.9% | -291.6% | +67.8% | -631.6% | at low |
| alltime | all time | at high | +119.9% | -291.6% | +67.8% | -631.6% | at low |
Amylyx Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$39.24 M(-26.3%) | -$212.04 M(+37.9%) |
| Jun 2024 | - | -$53.23 M(-56.3%) | -$153.78 M(+92.0%) |
| Mar 2024 | - | -$121.81 M(-5550.3%) | -$80.08 M(-300.7%) |
| Dec 2023 | $39.89 M(-119.9%) | $2.23 M(-88.3%) | $39.89 M(-690.4%) |
| Sep 2023 | - | $19.02 M(-7.1%) | -$6.76 M(-91.6%) |
| Jun 2023 | - | $20.48 M(-1207.7%) | -$80.29 M(-48.2%) |
| Mar 2023 | - | -$1.85 M(-95.8%) | -$154.92 M(-22.9%) |
| Dec 2022 | -$200.85 M | -$44.41 M(-18.5%) | -$200.85 M(+8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$54.52 M(+0.7%) | -$184.74 M(+20.6%) |
| Jun 2022 | - | -$54.15 M(+13.3%) | -$153.13 M(+30.3%) |
| Mar 2022 | - | -$47.78 M(+68.9%) | -$117.56 M(+42.3%) |
| Dec 2021 | -$82.64 M(+106.6%) | -$28.29 M(+23.5%) | -$82.64 M(+31.3%) |
| Sep 2021 | - | -$22.91 M(+23.3%) | -$62.93 M(+57.2%) |
| Jun 2021 | - | -$18.58 M(+44.5%) | -$40.02 M(+86.6%) |
| Mar 2021 | - | -$12.86 M(+49.7%) | -$21.45 M(+149.7%) |
| Dec 2020 | -$39.99 M(+221.5%) | -$8.59 M | -$8.59 M |
| Dec 2019 | -$12.44 M | - | - |
FAQ
- What is Amylyx Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals annual EBITDA year-on-year change?
- What is Amylyx Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Amylyx Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Amylyx Pharmaceuticals?
- What is Amylyx Pharmaceuticals TTM EBITDA year-on-year change?
What is Amylyx Pharmaceuticals annual EBITDA?
The current annual EBITDA of AMLX is $39.89 M
What is the all time high annual EBITDA for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high annual EBITDA is $39.89 M
What is Amylyx Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, AMLX annual EBITDA has changed by +$240.74 M (+119.86%)
What is Amylyx Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of AMLX is -$39.24 M
What is the all time high quarterly EBITDA for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high quarterly EBITDA is $20.48 M
What is Amylyx Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, AMLX quarterly EBITDA has changed by -$58.26 M (-306.27%)
What is Amylyx Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of AMLX is -$212.04 M
What is the all time high TTM EBITDA for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals all-time high TTM EBITDA is $39.89 M
What is Amylyx Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, AMLX TTM EBITDA has changed by -$205.29 M (-3038.60%)